Allergan receives authorisation for uveitis treatment
Allergan has announced that the European Medicines Agency (EMA) has extended the Marketing Authorisation for OZURDEX in the 27 member states of the EU to include the treatment of inflammation of the posterior segment of the eye presenting as non-infectious uveitis. OZURDEX is already available in many countries in Europe as the first treatment licensed for macular oedema in patients with retinal vein occlusion (RVO).
Latest Articles
Organising for Success
Professional and personal goals drive practice ownership and operational choices.
Update on Astigmatism Analysis
Is Frugal Innovation Possible in Ophthalmology?
Improving access through financially and environmentally sustainable innovation.
iNovation Innovators Den Boosts Eye Care Pioneers
New ideas and industry, colleague, and funding contacts among the benefits.
José Güell: Trends in Cornea Treatment
Endothelial damage, cellular treatments, human tissue, and infections are key concerns on the horizon.
Making IOLs a More Personal Choice
Surgeons may prefer some IOLs for their patients, but what about for themselves?
Need to Know: Higher-Order Aberrations and Polynomials
This first instalment in a tutorial series will discuss more on the measurement and clinical implications of HOAs.
Never Go In Blind
Novel ophthalmic block simulator promises higher rates of confidence and competence in trainees.
Simulators Benefit Surgeons and Patients
Helping young surgeons build confidence and expertise.